Tivicay 5 Mg 5mg Dispersible Tablet
PDF Leaflet Revision Date: 12 July 2012
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in combination with other antiretroviral medicines.
Dosage (summary)
Adults: 50 mg once daily; Dispersible tablets: 30 mg once daily for HIV-1 without resistance.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in the first trimester; use with caution in later trimesters.
Key Drug Interactions
- Dofetilide
- Pilsicainide
- Carbamazepine
- Rifampicin
- Metformin
Contraindications
- Severe hepatic impairment
- Hypersensitivity to dolutegravir
Common side effects
- Nausea
- Diarrhoea
- Headache
- Insomnia
- Rash
Counselling Points
- Take with or without food
- Monitor for signs of hypersensitivity
- Avoid antacids within 2 hours
Serious warnings
- Hypersensitivity reactions
- Immune Reconstitution Syndrome
Important Disclaimer
The Tivicay 5 Mg 5mg Dispersible Tablet professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
